OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies
ECCO '19 Copenhagen
2019
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis
ECCO '19 Copenhagen
2019
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
ECCO '19 Copenhagen
2019
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
ECCO '19 Copenhagen
2019
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
ECCO '19 Copenhagen
2019
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
ECCO '19 Copenhagen
2019
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease
ECCO '19 Copenhagen
2019
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
ECCO '19 Copenhagen
2019
OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease
ECCO '19 Copenhagen
2019
OP28: Host–microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis
ECCO '19 Copenhagen
2019
OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer
ECCO '19 Copenhagen
2019
OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis
ECCO '19 Copenhagen
2019
OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation
ECCO '19 Copenhagen
2019
OP32: A novel mechanism of colonic epithelial-T-cell cross-talk is dysregulated in IBD
ECCO '19 Copenhagen
2019
OP33: BUB1: a new player in the development of Crohn’s disease (CD)-associated fibrosisECCO '19 Copenhagen
2019
1
OP34: VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitisECCO '19 Copenhagen
2019